EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Combining Tumor Treating Fields with Immunotherapy in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidence, and Emerging Therapeutic Synergy

Douaa Albelal iD, Hari Krishnareddy Rachamala iD, Ishita Saha iD, Santanu Bhattacharya iD, Debabrata Mukhopadhyay iD, Hani M Babiker

Cells · 05.05.2026 · 15 (9) · 845

DOI: 10.3390/cells15090845 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 05.05.2026. Verfasst von Douaa Albelal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Mayo Clinic College of Medicine and Science, 4500 San Pablo Road South, Jacksonville, FL 32224, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Immunotherapy, Pancreatic Neoplasms. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: K-12 grant program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor Treating Fields (TTFields) represent a novel, non-invasive therapeutic modality in oncology that employs low-intensity, intermediate-frequency alternating electric fields to disrupt mitotic processes and induce cancer cell death. This review integrates mechanistic, preclinical, and emerging clinical evidence supporting the integration of TTFields with immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC). Although immunotherapy has transformed the treatment landscape across multiple malignancies, its efficacy in PDAC remains limited due to the tumor’s dense stroma, immunosuppressive microenvironment, and low immunogenicity. Preclinical investigations suggest that TTFields may potentiate immune-based therapies by enhancing antigen presentation, modulating the tumor microenvironment (TME), and attenuating mechanisms of immune resistance. We highlight studies evaluating TTFields in combination with immune checkpoint inhibitors (ICI), adoptive cellular therapies, and cancer vaccines, emphasizing their potential synergistic effects in PDAC. Clinically, the phase II PANOVA-2 trial demonstrated feasibility and encouraging survival outcomes with TTFields in combination with gemcitabine and nab-paclitaxel, providing the rationale for the ongoing phase III PANOVA-3 trial and the phase II PANOVA-4 trial, which combines TTFields with chemotherapy and atezolizumab. Additional clinical experiences in glioblastoma (GBM) and non-small-cell lung cancer (NSCLC) further substantiate the broader applicability of TTFields as an immunomodulatory adjunct. Remaining challenges include optimizing treatment sequencing, identifying predictive biomarkers, and managing TTFields-associated toxicities. Collectively, current evidence positions TTFields as a promising strategy to augment immunotherapy in PDAC, warranting further translational and clinical investigation to establish its role in reshaping therapeutic paradigms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalImmunotherapyPancreatic NeoplasmsHumansAnimalsCombined Modality TherapyTumor Microenvironment

Stichwörter der Autor:innen

combined therapyimmunotherapypancreatic ductal adenocarcinomatumor treating fields

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Mayo Clinic College of Medicine and Science, 4500 San Pablo Road South, Jacksonville, FL 32224, USA.
  • Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, 4500 San Pablo Road South, Jacksonville, FL 32224, USA.
  • Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, 4500 San Pablo Road South, Jacksonville, FL 32224, USA.
  • Department of Bioengineering, Mayo Clinic College of Medicine and Sciences, 4500 San Pablo Road South, Jacksonville, FL 32224, USA.

ORCID-Profile: Douaa Albelal, Hari Krishnareddy Rachamala, Ishita Saha, Santanu Bhattacharya, Debabrata Mukhopadhyay

Förderung

  • K-12 grant program

Zitieren

APA

Albelal, D., Rachamala, H. K., Saha, I., Bhattacharya, S., Mukhopadhyay, D., & Babiker, H. M. (2026). Combining Tumor Treating Fields with Immunotherapy in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidence, and Emerging Therapeutic Synergy. Cells, 15(9), 845. https://doi.org/10.3390/cells15090845

Vancouver

Albelal D, Rachamala HK, Saha I, Bhattacharya S, Mukhopadhyay D, Babiker HM. Combining Tumor Treating Fields with Immunotherapy in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidence, and Emerging Therapeutic Synergy. Cells. 2026;15(9):845. doi:10.3390/cells15090845

BibTeX
@article{Albelal2026,
  author = {Albelal, Douaa and Rachamala, Hari Krishnareddy and Saha, Ishita and Bhattacharya, Santanu and Mukhopadhyay, Debabrata and Babiker, Hani M},
  title = {Combining Tumor Treating Fields with Immunotherapy in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidence, and Emerging Therapeutic Synergy},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {9},
  pages = {845},
  doi = {10.3390/cells15090845}
}
Kostenlos starten →